Pabst Müller, Thomas Niklaus

Up a level
Export as [feed] RSS
Group by: Item Type | No Grouping
Number of items: 22.

Journal Article

Prediletto, Irene; Farag, Sarah Ahmed Ibrahim; Bacher, Vera Ulrike; Jeker, Barbara; Mansouri Taleghani, Behrouz; Bregy, Rachel; Zander, Thilo; Betticher, Daniel; Egger, Thomas; Novak, Urban; Pabst Müller, Thomas Niklaus (2019). High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients. Bone marrow transplantation, 54(12), pp. 1923-1925. Nature Publishing Group 10.1038/s41409-019-0508-2

Seipel, Katja; Schmitter, Karin; Bacher, Ulrike; Pabst Müller, Thomas Niklaus (2019). Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia. Cancers, 11(11) MDPI AG 10.3390/cancers11111779

Fassbind, Priska; Jeker, Barbara; Müller, Beatrice Ursula; Bacher, Vera Ulrike; Zimmerli, Stefan; Endrich, Olga; Gahl, Brigitta; Novak, Urban; Pabst Müller, Thomas Niklaus (2019). Improved survival rates of AML patients following admission to the intensive care unit. Leukemia & lymphoma, 60(10), pp. 2423-2431. Informa Healthcare 10.1080/10428194.2019.1594213

Ghilardi, Guido; Pabst Müller, Thomas Niklaus; Jeker, Barbara; Müller, Rouven; Cairoli, Anne; Müller, Antonia M S; Bargetzi, Mario; Hitz, Felicitas; Baldomero, Helen; Heim, Dominik; Schmidt, Adrian; Rossi, Davide; Ghielmini, Michele; Wannesson, Luciano; Lerch, Erika; Samaras, Panagiotis; Schanz, Urs; Passweg, Jakob R; Stussi, Georg; Kleber, Martina; ... (2019). Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study. Bone marrow transplantation, 54(7), pp. 1029-1037. Nature Publishing Group 10.1038/s41409-018-0379-y

Zeijlemaker, Wendelien; Grob, Tim; Meijer, Rosa; Hanekamp, Diana; Kelder, Angèle; Carbaat-Ham, Jannemieke C; Oussoren-Brockhoff, Yvonne J M; Snel, Alexander N; Veldhuizen, Dennis; Scholten, Willemijn J; Maertens, Johan; Breems, Dimitri A; Pabst Müller, Thomas Niklaus; Manz, Markus G; van der Velden, Vincent H J; Slomp, Jennichjen; Preijers, Frank; Cloos, Jacqueline; van de Loosdrecht, Arjan A; Löwenberg, Bob; ... (2019). CD34CD38 leukemic stem cell frequency to predict outcome in acute myeloid leukemia. Leukemia, 33(5), pp. 1102-1112. Nature Publishing Group 10.1038/s41375-018-0326-3

Jeker, Barbara; Pabst Müller, Thomas Niklaus; Novak, Urban (2019). CAR-T-Zelltherapie – eine neue Behandlungsoption. Info@Onkologie, 2019(1), pp. 18-20. Aerzteverlag medinfo AG

Borchmann, Peter; Goergen, Helen; Kobe, Carsten; Lohri, Andreas; Greil, Richard; Eichenauer, Dennis A; Zijlstra, Josée M; Markova, Jana; Meissner, Julia; Feuring-Buske, Michaela; Hüttmann, Andreas; Dierlamm, Judith; Soekler, Martin; Beck, Hans-Joachim; Willenbacher, Wolfgang; Ludwig, Wolf-Dieter; Pabst Müller, Thomas Niklaus; Topp, Max S; Hitz, Felicitas; Bentz, Martin; ... (2018). PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet, 390(10114), pp. 2790-2802. Elsevier 10.1016/S0140-6736(17)32134-7

Mueller, Beatrice U; Seipel, Katja; Pabst Müller, Thomas Niklaus (2018). Myelodysplastic syndromes and acute myeloid leukemias in the elderly. European journal of internal medicine, 58, pp. 28-32. Elsevier 10.1016/j.ejim.2018.05.026

Driessen, Christoph; Müller, Rouven; Novak, Urban; Cantoni, Nathan; Betticher, Daniel; Mach, Nicolas; Rüfer, Axel; Mey, Ulrich; Samaras, Panagiotis; Ribi, Karin; Besse, Lenka; Besse, Andrej; Berset, Catherine; Rondeau, Stephanie; Hawle, Hanne; Hitz, Felicitas; Pabst Müller, Thomas Niklaus; Zander, Thilo (2018). Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma. Blood, 132(19), pp. 2097-2100. American Society of Hematology 10.1182/blood-2018-05-851170

Seipel, Katja; Marques, Miguel A T; Sidler, Corinne; Mueller, Beatrice U; Pabst Müller, Thomas Niklaus (2018). MDM2- and FLT3-inhibitors in the treatment of -ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin. Haematologica - the hematology journal, 103(11), pp. 1862-1872. Ferrata-Storti Foundation 10.3324/haematol.2018.191650

Farag, Sarah Ahmed Ibrahim; Jeker, Barbara; Bacher, Vera Ulrike; Mansouri Taleghani, Behrouz; Müller, Beatrice Ursula; Novak, Urban; Pabst Müller, Thomas Niklaus (2018). Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients. Hematological oncology, 36(4), pp. 671-678. Wiley 10.1002/hon.2546

von Tresckow, Bastian; Kreissl, Stefanie; Goergen, Helen; Bröckelmann, Paul J; Pabst Müller, Thomas Niklaus; Fridrik, Michael; Rummel, Mathias; Jung, Wolfram; Thiemer, Julia; Sasse, Stephanie; Bürkle, Carolin; Baues, Christian; Diehl, Volker; Engert, Andreas; Borchmann, Peter (2018). Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. The Lancet. Haematology, 5(10), e462-e473. Elsevier 10.1016/S2352-3026(18)30140-6

Simonis, Alexander; Fux, Michaela; Nair, Gayathri; Mueller, Nicolas J; Haralambieva, Eugenia; Pabst Müller, Thomas Niklaus; Pachlopnik Schmid, Jana; Schmidt, Adrian; Schanz, Urs; Manz, Markus G; Müller, Antonia M S (2018). Allogeneic hematopoietic cell transplantation in patients with GATA2 deficiency-a case report and comprehensive review of the literature. Annals of hematology, 97(10), pp. 1961-1973. Springer-Verlag 10.1007/s00277-018-3388-4

Huguet, Françoise; Chevret, Sylvie; Leguay, Thibaut; Thomas, Xavier; Boissel, Nicolas; Escoffre-Barbe, Martine; Chevallier, Patrice; Hunault, Mathilde; Vey, Norbert; Bonmati, Caroline; Lepretre, Stéphane; Marolleau, Jean-Pierre; Pabst Müller, Thomas Niklaus; Rousselot, Philippe; Buzyn, Agnès; Cahn, Jean-Yves; Lhéritier, Véronique; Béné, Marie C; Asnafi, Vahid; Delabesse, Eric; ... (2018). Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial. Journal of clinical oncology, 36(24), pp. 2514-2523. American Society of Clinical Oncology 10.1200/JCO.2017.76.8192

Gorin, Norbert Claude; Labopin, Myriam; Blaise, Didier; Dumas, Pierre-Yves; Pabst Müller, Thomas Niklaus; Trisolini, Silvia Maria; Arcese, William; Houhou, Mohamed; Mohty, Mohamad; Nagler, Arnon (2018). Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMT. American journal of hematology, 93(7), pp. 859-866. Wiley-Liss 10.1002/ajh.25105

Gössi, Flavio; Spahn, Martin; Samaras, Panagiotis; Beyer, Jörg; Schardt, Julian; Pabst Müller, Thomas Niklaus (2018). Response to first-line treatment and histology are associated with achieving complete remission after the first salvage high-dose chemotherapy in relapsing germ cell tumor patients. Bone marrow transplantation, 53(7), pp. 820-825. Nature Publishing Group 10.1038/s41409-018-0089-5

Junge, Alexandra; Bacher, Vera Ulrike; Mueller, Beatrice U; Keller, Peter; Solenthaler, Max; Pabst Müller, Thomas Niklaus (2018). Adverse outcome of AML with aberrant CD16 and CD56 NK cell marker expression. (In Press). Hematological oncology Wiley 10.1002/hon.2516

Shumilov, Evgenii; Flach, Johanna; Pabst Müller, Thomas Niklaus; Fiedler, Georg Martin; Angelillo, Anne; Trümper, Lorenz; Joncourt, Raphael; Kohlmann, Alexander; Bacher, Vera Ulrike (2018). Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology. Critical reviews in oncology, hematology, 126, pp. 64-79. Elsevier 10.1016/j.critrevonc.2018.03.020

Seipel, Katja; Marques, Miguel A T; Sidler, Corinne; Mueller, Beatrice U; Pabst Müller, Thomas Niklaus (2018). The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia. Cancers, 10(6) MDPI AG 10.3390/cancers10060170

Bacher, Vera Ulrike; Pabst Müller, Thomas Niklaus (2018). Aktuelle Entwicklungen in der hämato-onkologischen Diagnostik. JATROS. Hämatologie & Onkologie, 2018(5), pp. 46-49. Universimed

Jongen-Lavrencic, Mojca; Grob, Tim; Hanekamp, Diana; Kavelaars, François G; Al Hinai, Adil; Zeilemaker, Annelieke; Erpelinck-Verschueren, Claudia A J; Gradowska, Patrycja L; Meijer, Rosa; Cloos, Jacqueline; Biemond, Bart J; Graux, Carlos; van Marwijk Kooy, Marinus; Manz, Markus G; Pabst Müller, Thomas Niklaus; Passweg, Jakob R; Havelange, Violaine; Ossenkoppele, Gert J; Sanders, Mathijs A; Schuurhuis, Gerrit J; ... (2018). Molecular Minimal Residual Disease in Acute Myeloid Leukemia. New England journal of medicine NEJM, 378(13), pp. 1189-1199. Massachusetts Medical Society MMS 10.1056/NEJMoa1716863

Mathew, Nimitha R; Baumgartner, Francis; Braun, Lukas; O'Sullivan, David; Thomas, Simone; Waterhouse, Miguel; Müller, Tony A; Hanke, Kathrin; Taromi, Sanaz; Apostolova, Petya; Illert, Anna L; Melchinger, Wolfgang; Duquesne, Sandra; Schmitt-Graeff, Annette; Osswald, Lena; Yan, Kai-Li; Weber, Arnim; Tugues, Sonia; Spath, Sabine; Pfeifer, Dietmar; ... (2018). Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nature medicine, 24(3), pp. 282-291. Nature Publishing Group 10.1038/nm.4484

This list was generated on Fri Jun 5 18:58:28 2020 CEST.
Provide Feedback